Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) had its price objective decreased by Robert W. Baird from $24.00 to $20.00 in a report issued on Friday, MarketBeat reports. Robert W. Baird currently has an outperform rating on the biopharmaceutical company’s stock. MRNS has been the topic of a number of other reports. Truist Financial cut their […]
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) insider Christina Shafer sold 2,385 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $9.52, for a total value of $22,705.20. Following the completion of the sale, the insider now directly owns 40,637 shares of […]
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) insider Christina Shafer sold 2,385 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $9.52, for a total value of $22,705.20. Following the completion of the sale, the insider now directly owns 40,637 shares […]
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) CFO Steven Pfanstiel sold 2,790 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $9.54, for a total transaction of $26,616.60. Following the completion of the sale, the chief financial officer now owns 49,338 shares […]
Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued a report on the stock in […]